SERPIND1

(redirected from HC-II)

SERPIND1

A gene on chromosome 22q11.21 that encodes a member of the serine protease inhibitor (serpin) family that rapidly inhibits thrombin in the presence of dermatan sulfate or heparin. SERPIND1 shares homology with antithrombin III and other members of the alpha 1-antitrypsin superfamily.

Molecular pathology
SERPIND1 mutations are associated with heparin cofactor-II deficiency.
References in periodicals archive ?
In the US, the current HC-II test retails for about US$22 per test, takes 6-7 h to process, and requires access to laboratory equipment and a computer (36).
This study was undertaken to compare the diagnostic accuracy of HPV testing by hybrid capture II (HC-II) with conventional cervical smear cytology for squamous intraepithelial lesions (SIL).
Patients, in whom conventional cytology, HC-II test and colposcopy-directed biopsy were done, formed the basis of this study.
Sensitivity and specificity of cytology for detection of H-SIL and above lesions was 93.33 and 83.49 per cent while for HC-II it was 93.33 and 90.83 per cent, respectively.
Interpretation & conclusion: The main utility of HC-II is in the triage of patients with cytology smear diagnosis of ASC-US, ASC-H or L-SIL, for referral to colposcopic examination.
As part of a large study examining screening for cervical cancer, this study was undertaken to compare the diagnostic accuracy of HPV testing by hybrid capture II (HC-II) with conventional cervical smear cytology.
Patients were called again for biopsy when either cytology report or HC-II was positive, if biopsy had not already been performed.
Specimen for HC-II was obtained in the same sitting, immediately after making the conventional cytology smear, using a conical brush and a vial containing the specimen transport medium (STM), both obtained from the manufacturer of HC-II (Digene Corporation, Maryland, USA).
HPV testing was done using HC-II assay (Digene Corporation, Maryland, USA) following the manufacturer's instructions.
HC-II testing: High-risk HPV infection was seen in 25 patients (18.80%).
This selective screening method was adopted to increase the yield of positive cases; so that the utility of HC-II could be evaluated without unnecessarily increasing the sample size.